Relaying what matters next.

A standardized, tissue specific multi-omics map of senescent cell states puts validated biomarkers into the hands of researchers. The result is a clear path to precision diagnostics, smarter trials, and the next wave of senotherapeutics.

FERC’s 2025 approval of inverter-based resource reliability standards turns grid support from best effort to requirement. This playbook shows developers, owners, and grid operators how to comply in 2025 to 2026 and convert upgrades into revenue.

Arbitrum’s BoLD upgrade removes validator allowlists, timeboxes disputes, and opens Layer 2 verification to anyone. Here is what permissionless proofs mean for Stage 2, withdrawal timelines, risk models, and institutional adoption.

A new enterprise AI showdown is here. Google debuts Gemini Enterprise while OpenAI launches AgentKit, with AWS AgentCore close behind. We compare capabilities, build paths, and lock-in risks, then give you a 30/60/90-day plan to ship.

BWXT has started core manufacturing for the Defense Department’s Project Pele microreactor, moving the program from design reviews to real hardware. Here is what that shift means for microgrids, logistics, and edge compute over the next two years.

A wave of 2025 OSK data in primates and metabolic models is pulling partial epigenetic reprogramming toward the clinic. Learn why ophthalmology leads, how control systems make it feasible, and what to watch next.

Launched in May 2025, China’s Tianwen‑2 is on course to sample Earth’s quasi‑moon Kamoʻoalewa, then use an Earth swingby to set up a second act at active asteroid 311P. One spacecraft, two targets, a faster, cheaper deep‑space playbook.

Salesforce is preparing voice-native, hybrid-reasoning agents that can listen, speak, plan, and act across your stack. Here is what it means for contact centers, how it compares to ServiceNow and Sierra, and a 90-day playbook to deploy safely.

In February 2025, the FDA accepted preliminary efficacy (RXE) for a senior-dog longevity pill and expanded conditional approval rules now give it a path to market. Together they create the first large, real-world testbed for geroprotectors and may shorten the road to human aging therapies.

NASA’s Lunar Terrain Vehicle is heading toward a 2025 downselect. Inside the rival designs: how they plan to survive polar night, work the shadowed rims, and turn short landings into a lasting foothold at the Moon’s south pole.

Washington’s permit restart uncorked a wave of U.S. LNG approvals. Here is what can truly reach FID and first cargo by 2026–2030, and how it will ripple through Henry Hub, Europe, Asia, and shipping.

On March 26, 2025, Celo completed its move from an independent Layer 1 to an OP Stack Layer 2 on Ethereum. The shift promises cheaper fees, stronger mobile UX, and stablecoin-as-gas while signaling a broader consolidation toward Ethereum’s Superchain.

OpenAI is turning chat into a checkout counter. Here is what ChatGPT Instant Checkout and the Agentic Commerce Protocol mean for developers, brands, and the next wave of agent-driven shopping.

A September 17–18, 2025 vote created generic listing standards that can cut crypto ETF timelines from roughly 240 days to as few as 75. Here is why Solana and XRP likely lead, how the new rules reshape liquidity and volatility, and what traders should do in Q4.

Firefly’s October 2025 deal to acquire SciTec shifts the conversation from fast rockets to full stack space power. Pairing rapid launch with on-orbit sensors and mission-grade ground software could cut cueing from minutes to seconds and make pop-up constellations operational, not experimental.

Meta’s new Ray-Ban Display glasses and Neural Band turn on‑lens cards and silent EMG gestures into a complete loop for ambient computing. Here’s what shipped, why it matters, and how builders can design for glance-and-gesture first.

A September 8, 2025 MIT-led analysis of JWST observations rules out a hydrogen-rich sky and makes a Venus or Mars style carbon dioxide atmosphere unlikely on TRAPPIST-1e. The hunt now shifts to cooler, nitrogen-dominated options and a two-year plan that treats the star as part of the instrument.

In June 2025, Vertex’s stem cell islet therapy zimislecel posted Phase 1/2 results with A1c under 7 percent and insulin independence for most at one year, pivoting the field from devices toward immunosuppression-first strategies.